Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients
Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can cause hematologic toxicities. Prior studies in OLT have demonstrated comparable efficacy of low dose (LD)-VGCV to oral ganciclovir, but the efficacy of LD-VGCV compared to standard dose (SD) VGCV has not been established. Herein we describe the first report comparing LD-VGCV to SD-VGCV for the prevention of CMV in OLT.
Payne, Chelsea; Melaragno, Jennifer I.; Hutchinson, David; Babu, Tara M.; Prasad, Paritosh; and Dick, Travis B. (2017). "Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients." American Journal of Transplantation 17.S3, 577-578.
Please note that the Publication Information provides general citation information and may not be appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit http://libguides.sjfc.edu/citations.